Genetic Peptide Testing: What It Can and Cannot Tell You

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Understanding your genetics starts with understanding what a test can measure—and what it cannot.

The PlexusDx GLP-1 & Peptide Pathways Genetic Test analyzes selected DNA variants and presents related information in the GLP-1 & Peptide Pathways Report. Its educational topics include metabolism, muscle biology, aging, cognition, and other health-related processes. It is a DNA test, not a measurement of the peptides circulating in your body.

A pathway-level genetic finding should not be used to choose a peptide, determine a dose, or conclude that a medication will be safe or effective for you. Those conclusions require evidence specific to the clinical question—not simply a connection between a gene and a biological process.^[1]

What does “genetic peptide testing” mean here?

In this product’s name, “peptide pathways” refers to biological topics used to organize genetic information. The test examines selected locations in DNA using a cheek-swab sample. The accompanying report explains the variants it analyzes in the context of related research.

This is different from directly measuring hormone levels, receptor activity, or a medication’s concentration in the body. It is also different from testing whether a person will respond to a particular treatment.

The report’s topic areas are educational categories. A section concerning muscle biology does not establish a need for a muscle-building compound. A section concerning cognition does not identify an appropriate cognitive treatment. A longevity-related finding does not establish that an intervention will extend a person’s life.

A genetic association is not a treatment recommendation

Researchers may find that a genetic variant is associated with a trait or a biological process. That does not automatically show that a drug targeting a related process will benefit someone with that variant.

There are separate questions to answer: Can the laboratory identify the variant accurately? Does the interpretation have evidence for the claimed health relationship? Does using the result to make a medical decision improve care? These are different kinds of evidence.^[2]

For this report, the appropriate focus is understanding the selected variants and the limits of their interpretation. It should not be used to rank peptides, identify a “best match,” recommend combinations, explain treatment failure, or establish the need for a compounded medication.

What about research linking genetics to GLP-1 treatment response?

Some genetic tests have established applications for specific medicines. That does not mean every genetic panel can predict medication response. Evidence must support the particular variant, drug, and interpretation being claimed; genetics is also only one factor that may affect treatment response.^[1]

For example, a 2025 study investigated a genetic score involving NBEA and weight-loss outcomes in people prescribed GLP-1 receptor agonists. That research concerns the particular score and outcomes studied. It does not establish the performance of a different genetic panel or demonstrate that pathway-based recommendations improve outcomes across other peptides.^[3]

This article does not present that study as clinical validation of the PlexusDx report. The report should not be used to decide whether to start, stop, switch, or change the dose of a GLP-1 medication.

Genetic findings do not establish a peptide’s regulatory status

A genetic result cannot make an investigational compound FDA-approved or establish that it is appropriate for human use. Mentioning a compound in scientific literature does not mean it has been approved as a treatment.

Compounded medications are not FDA-approved, and their preparation and dispensing must independently satisfy applicable federal and state requirements. A genetic pathway result is not a substitute for those requirements or for a patient-specific medical assessment.^[4]

FDA has also warned consumers about unapproved GLP-1 products sold under research-use labels. A “research use only” label is not evidence that a product is safe to use as a medication.^[5]

Laboratory quality and clinical usefulness are different

CLIA certification addresses laboratory quality requirements. It does not, by itself, establish that a genetic report can select an effective treatment or predict a patient’s response. Clinical validity and clinical usefulness require their own supporting evidence.^[2]

Laboratory credentials should not be interpreted as FDA approval or clearance of a report’s treatment-related interpretations—or of any compound discussed alongside them.

How to approach your results

Begin with the report’s stated purpose, the variants examined, and the limitations of the evidence. Useful questions include: What did the cited study actually measure? Does the finding concern a general trait or a specific medication? What remains uncertain?

A qualified healthcare provider or genetic counselor can help explain the relevance and limitations of genetic information. FDA advises that consumer genetic reports are not substitutes for clinical evaluation and should not be used to determine treatment.^[6]

Scientific interpretations can change as evidence develops. A report should not be treated as a permanent set of treatment instructions.^[6]

Frequently asked questions

Does this test tell me which peptide to use?

It should not be used for that purpose. Its intended scope is educational genetic information, not peptide selection, dosing, or prediction of an individual treatment outcome.

Does a pathway finding mean I have a deficiency or need treatment?

No. A finding at a selected DNA location is not a direct measurement of peptide levels and does not, by itself, establish a deficiency or a need for treatment.

Should I buy this test to find out why a medication is not working?

This report should not be used to diagnose medication non-response or decide how to change treatment. Discuss those concerns with your prescribing clinician.

Learn more about the genetic test and report

Review the GLP-1 & Peptide Pathways Genetic Test and GLP-1 & Peptide Pathways Report for information about the sample, report content, and intended educational use. These are genetic-information products, not peptide medications.

This article is educational and does not provide a diagnosis, prescription, or recommendation to use a peptide or other medication.

Sources

1. FDA: Table of Pharmacogenetic Associations.
2. MedlinePlus Genetics: How can I be sure a genetic test is valid and useful?
3. Mariam-Smith et al. Neurobeachin (NBEA) is a novel gene associated with GLP-1 receptor agonist associated weight loss. Diabetes, Obesity and Metabolism. 2025.
4. FDA: Compounding and the FDA: Questions and Answers.
5. FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
6. FDA: Direct-to-Consumer Tests.